-Demonstrates How Clinically Proven Celadrin(R) Achieves Its Results
SAN DIEGO, March 19 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX), announced today that Director of Research and Development, Dr. Robert Hesslink, presented basic research outlining the cellular pathway instrumental in the efficacy of Celadrin(R). Dr. Hesslink outlined the pathway before an audience of scientists and industry leaders at the Nutrigenomics 2008 meeting in Paris, France. The meeting was sponsored by the International Society of Antioxidant in Nutrition and Health and held at the prestigious Universite Paris V, Faculte de Medecine Paris Descartes.
The clinical efficacy of Celadrin(R) has been published in such esteemed journals as the Journal of Rheumatology and the Journal of Strength Conditioning and Research. It has been shown that Celadrin(R) reduces joint and muscular discomfort within 30 minutes of topical application and within 14 days of oral consumption.
In Paris, Dr. Hesslink presented research from radio tracer label data and ligand binding assays supporting the hypothesis that Celadrin(R) interacts with membrane receptors involved with the inflammatory cascade. To support this hypothesis, Dr. Hesslink presented dual-label tracer data from the laboratory of Dr. Daniel Gallaher at the University of Minnesota showing the appearance of the labeled components of Celadrin(R) in the phospholipid fractions. The greatest amount of the label was found in the phospholipid fractions of liver homogenates (e.g. microsomes) and white blood cell microsomes.
In addition, Dr. Hesslink presented in vitro and binding assay studies
conducted by a world leading clinical discovery organization for the
pharmaceutical and biotechnology industries. In these in vitro studies,
Celadrin(R) was shown to inhibit the thromboxane synthase enzyme using
prostaglandin G2 (PGG2) and prostaglandin H2 (PGH2) as substrates.
Thromboxane is a very strong fa
|SOURCE Imagenetix, Inc.|
Copyright©2008 PR Newswire.
All rights reserved